Detalles de la búsqueda
1.
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
Br J Haematol;
162(2): 229-39, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23672349
2.
Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.
Leuk Lymphoma;
61(1): 98-107, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31409168
3.
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Expert Rev Hematol;
10(10): 933-939, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28885063
4.
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Adv Hematol;
2015: 848473, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26635878
Resultados
1 -
4
de 4
1
Próxima >
>>